Clinical Trials Logo

Clinical Trial Summary

Patients with an ileal pouch-anal anastomosis(IPAA; pouch) due to refractory inflammatory bowel disease and increased bowel frequency in the absence of significant pouch inflammation will be randomized to liraglutide or placebo in a prospective cross over study.


Clinical Trial Description

Randomized, double-blind, 2-period, placebo- controlled, crossover proof of concept study. Ten patients with increased bowel frequency defined as bowel frequency > 8 bowel movements in 24 hours on at least 4 of 7 days/week and presence of high bowel frequency > 4 weeks despite adequate therapy for acute pouchitis or Crohn's like disease of the pouch will be randomized to either liraglutide or placebo treatment for 6 weeks (Period 1). Subjects will be randomized 1:1 to 1 of 2 treatment sequences, liraglutide-placebo or placebo-liraglutide, and receive either liraglutide or volume-matched placebo. After a wash-out period of at least 5 days (the half-life of liraglutide is 11-12 hours, thus the minimal washout period of 5 days is equal to 10 half-life's) patients will be crossed over to the other treatment arm (Period 2). Since high bowel frequency can result in significant malaise and dehydration, patients not responding to the respective therapies in period 1 may be crossed over after 4 weeks of therapy or in period 2 can be terminated early at week 4. The rationale behind the early termination is based on 2 open-label cohorts reporting the efficacy of liraglutide or exenatide in patients with high output ileostomies (the patient group the most comparable to the pouch patient population). Glucagon-like peptide- 1 (GLP-1) receptor agonist therapy even at the lowest dose showed an almost immediate effect reducing the ostomy output after 1-3 days in most patients.Thus, patients not responding to a 4-week therapy with a GLP-1receptor agonist are highly unlikely to respond if the therapy would be continued. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04763564
Study type Interventional
Source University of North Carolina, Chapel Hill
Contact
Status Completed
Phase Phase 2
Start date March 22, 2022
Completion date October 16, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT04979832 - GM-CSF, Fosfomycin and Metronidazole for Pouchitis in Ulcerative Colitis Patients After Restorative IPAA Surgery Phase 1/Phase 2
Terminated NCT00061282 - Clotrimazole Enemas for Pouchitis in Children and Adults Phase 1/Phase 2
Not yet recruiting NCT05829109 - Fecal Microbiota Transplant for Patients With Chronic Pouchitis Early Phase 1
Recruiting NCT03136419 - Microbiota and Immune microEnvironment in Pouchitis N/A
Withdrawn NCT04640155 - Treating Chronic Pouchitis With a Low FODMAP Diet N/A
Completed NCT02201186 - To Determine the Effect of Honey Enema in the Treatment of Patients With Acute Pouchitis Phase 2
Completed NCT02790138 - A Study to Evaluate the Efficacy and Safety of Vedolizumab in the Treatment of Chronic Pouchitis Phase 4
Not yet recruiting NCT01202396 - The Interaction Between Intestinal Microbiota, Innate Defense and Epithelial Integrity in the Development of Pouchitis N/A
Completed NCT02428361 - Fecal Microbiota Transplant (FMT) for Pouchitis Early Phase 1
Completed NCT03538366 - Fecal Microbiota Transplantation for Chronic Pouchitis N/A
Terminated NCT00583531 - Safety and Efficacy of AST-120 in the Treatment of Antibiotic-Refractory Pouchitis Phase 2
Recruiting NCT03524352 - the Prophylaxis of Recurrent Pouchitis After Fecal Microbiota Transplant in UC With Ileo-anal Anastomosis Phase 3
Completed NCT04820413 - Faecal Microbiota Transplantation From Normal Pouch Function Donor in the Treatment of Chronic Pouchitis N/A
Not yet recruiting NCT06443502 - A Study to Learn About the Safety of Vedolizumab and How Well it Works in Children and Teenagers With Active Chronic Pouchitis Phase 3
Recruiting NCT04089345 - Stelara fOr ChRonic AntibioTic rEfractory pouchitiS Phase 3
Not yet recruiting NCT03526796 - Hyperbaric Oxygen Therapy for Antibiotic Refractory Pouchitis N/A
Terminated NCT02782325 - Safety and Efficacy of Fecal Microbiome Transplantation (FMT) in the Treatment of Antibiotic Dependent Pouchitis (ADP) Phase 1/Phase 2
Completed NCT02828410 - Nutritional Impact of Serum-Derived Bovine Immunoglobulin Protein Isolate in Subjects With IPAA N/A
Recruiting NCT05578313 - Inflammatory Bowel Diseases (IBD) Cannabis Registry
Not yet recruiting NCT06316999 - Intestinal Ultrasound for the Evaluation of Pouchitis and Other Outcomes After Ileal Pouch-Anal Anastomosis N/A